Sartore-Bianchi et al., " Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer, " Ann. Onc., 17(suppl. 2): ii49-ii51 (2006).Sartore-Bianchi A,Cerea G,Schiavetto I,et al.Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. Annals...
Antibodies were purified by affinity-chromatography using epitope-specific peptide. Concentration: 1.0mg / ml Formulation: Supplied at 1.0mg / mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Storage: Store at -20°C for ...
Antibodies were purified by affinity-chromatography using epitope-specific peptide. Concentration: 1.0mg / ml Formulation: Supplied at 1.0mg / mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Storage: Store at -20°C for ...
The incidence of antibodies to JMT101 was low (18/132, 13.6%). Among all positive samples, three samples had antibody titer greater than 10. No patients had persistent antibody positivity. Neither antibody positivity nor antibody titer exerted evident impact on pharmacokinetics, efficacy, and safety...
Given that the development of brigatinib is now in the late phase of clinical trials and anti-EGFR antibodies are now broadly used clinically for several cancers other than lung cancer, the findings of this study should help to overcome the acquired resistance to third-generation EGFR–TKIs. ...
A significant fraction of non-small cell lung cancer (NSCLC) cases are due to oncogenic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Anti-EGFR antibodies have shown limited clinical benefit for NSCLC, whereas tyrosine kinase inhibitors (TKIs) are ...
ABN202 is an antibody-cytokine fusion protein (ACFP) that serves as a platform technology compromising the IFN-β mutein (ABN102) fused to various antibodies for specific tumor targeting. In a previous study, we designed ABN202 (αEGFR) to comprise an EGFR targeting antibody (Cetuximab) and ...
Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often driven by acquisition of mutations in the extracellular domain (ECD) of EGFR. Sym004 is a nove...
Sci. 2012, 13, 12000-12016; doi:10.3390/ijms130912000 Article OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity...
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin. Cancer Res. 2014, 20, 3775–3786. [Google Scholar] [CrossRef] [Green Version] Pranteda, A.; Piastra, V.; ...